FDA Recalls Finder

FDA approves Voraxaze to treat patients with toxic methotrexate levels
17 January 2012, 3:58 pm

The U.S. Food and Drug Administration today approved Voraxaze (glucarpidase) to treat patients with toxic levels of methotrexate in their blood due to kidney failure. Methotrexate is a commonly used cancer chemotherapy drug normally eliminated from the body by the kidneys. However, patients receiving high doses of methotrexate may develop kidney failure.

Source: Food and Drug Administration--Press Releases